205 related articles for article (PubMed ID: 21108978)
1. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
Nowacek AS; Balkundi S; McMillan J; Roy U; Martinez-Skinner A; Mosley RL; Kanmogne G; Kabanov AV; Bronich T; Gendelman HE
J Control Release; 2011 Mar; 150(2):204-11. PubMed ID: 21108978
[TBL] [Abstract][Full Text] [Related]
2. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
Nowacek AS; McMillan J; Miller R; Anderson A; Rabinow B; Gendelman HE
J Neuroimmune Pharmacol; 2010 Dec; 5(4):592-601. PubMed ID: 20237859
[TBL] [Abstract][Full Text] [Related]
3. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.
Balkundi S; Nowacek AS; Veerubhotla RS; Chen H; Martinez-Skinner A; Roy U; Mosley RL; Kanmogne G; Liu X; Kabanov AV; Bronich T; McMillan J; Gendelman HE
Int J Nanomedicine; 2011; 6():3393-404. PubMed ID: 22267924
[TBL] [Abstract][Full Text] [Related]
4. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.
Nowacek AS; Miller RL; McMillan J; Kanmogne G; Kanmogne M; Mosley RL; Ma Z; Graham S; Chaubal M; Werling J; Rabinow B; Dou H; Gendelman HE
Nanomedicine (Lond); 2009 Dec; 4(8):903-17. PubMed ID: 19958227
[TBL] [Abstract][Full Text] [Related]
5. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.
Guo D; Zhang G; Wysocki TA; Wysocki BJ; Gelbard HA; Liu XM; McMillan JM; Gendelman HE
J Virol; 2014 Sep; 88(17):9504-13. PubMed ID: 24920821
[TBL] [Abstract][Full Text] [Related]
6. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.
Puligujja P; McMillan J; Kendrick L; Li T; Balkundi S; Smith N; Veerubhotla RS; Edagwa BJ; Kabanov AV; Bronich T; Gendelman HE; Liu XM
Nanomedicine; 2013 Nov; 9(8):1263-73. PubMed ID: 23680933
[TBL] [Abstract][Full Text] [Related]
7. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Kanmogne GD; Singh S; Roy U; Liu X; McMillan J; Gorantla S; Balkundi S; Smith N; Alnouti Y; Gautam N; Zhou Y; Poluektova L; Kabanov A; Bronich T; Gendelman HE
Int J Nanomedicine; 2012; 7():2373-88. PubMed ID: 22661891
[TBL] [Abstract][Full Text] [Related]
8. Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.
Martinez-Skinner AL; Veerubhotla RS; Liu H; Xiong H; Yu F; McMillan JM; Gendelman HE
J Proteome Res; 2013 May; 12(5):2282-94. PubMed ID: 23544708
[TBL] [Abstract][Full Text] [Related]
9. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
Dash PK; Gendelman HE; Roy U; Balkundi S; Alnouti Y; Mosley RL; Gelbard HA; McMillan J; Gorantla S; Poluektova LY
AIDS; 2012 Nov; 26(17):2135-44. PubMed ID: 22824628
[TBL] [Abstract][Full Text] [Related]
10. Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.
Araínga M; Guo D; Wiederin J; Ciborowski P; McMillan J; Gendelman HE
Retrovirology; 2015 Jan; 12():5. PubMed ID: 25608975
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.
Puligujja P; Balkundi SS; Kendrick LM; Baldridge HM; Hilaire JR; Bade AN; Dash PK; Zhang G; Poluektova LY; Gorantla S; Liu XM; Ying T; Feng Y; Wang Y; Dimitrov DS; McMillan JM; Gendelman HE
Biomaterials; 2015 Feb; 41():141-50. PubMed ID: 25522973
[TBL] [Abstract][Full Text] [Related]
12. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.
Huang J; Gautam N; Bathena SP; Roy U; McMillan J; Gendelman HE; Alnouti Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2332-8. PubMed ID: 21752731
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage.
Bressani RF; Nowacek AS; Singh S; Balkundi S; Rabinow B; McMillan J; Gendelman HE; Kanmogne GD
Nanotoxicology; 2011 Dec; 5(4):592-605. PubMed ID: 21175298
[TBL] [Abstract][Full Text] [Related]
14. Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs.
Balkundi S; Nowacek AS; Roy U; Martinez-Skinner A; McMillan J; Gendelman HE
J Vis Exp; 2010 Dec; (46):. PubMed ID: 21178968
[TBL] [Abstract][Full Text] [Related]
15. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
[TBL] [Abstract][Full Text] [Related]
16. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
[TBL] [Abstract][Full Text] [Related]
17. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
Siccardi M; Marzolini C; Seden K; Almond L; Kirov A; Khoo S; Owen A; Back D
Clin Pharmacokinet; 2013 Jul; 52(7):583-92. PubMed ID: 23479398
[TBL] [Abstract][Full Text] [Related]
18. Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Mehling M; Drechsler H; Kuhle J; Hardmeier M; Doerries R; Ruegg S; Gass A
J Neurovirol; 2008 Jan; 14(1):78-84. PubMed ID: 18300078
[TBL] [Abstract][Full Text] [Related]
19. Modulating cellular autophagy for controlled antiretroviral drug release.
Thomas MB; Gnanadhas DP; Dash PK; Machhi J; Lin Z; McMillan J; Edagwa B; Gelbard H; Gendelman HE; Gorantla S
Nanomedicine (Lond); 2018 Sep; 13(17):2139-2154. PubMed ID: 30129397
[TBL] [Abstract][Full Text] [Related]
20. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.
Dou H; Grotepas CB; McMillan JM; Destache CJ; Chaubal M; Werling J; Kipp J; Rabinow B; Gendelman HE
J Immunol; 2009 Jul; 183(1):661-9. PubMed ID: 19535632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
